Report Published: "France Pharmaceuticals & Healthcare Report Q3 2016"

Despite the ongoing recovery in some high frequency indicators, subdued economic growth in France relative to regional peers will continue to weigh on the French government spending potential, posing downside risks to our pharmaceutical and healthcare sector forecasts. In line with our view in the previous quarter, France's lack of structural reform will continue to tarnish the country's appeal to pharmaceutical investors. That said, France's position as one of the three largest pharmaceutical markets in Western Europe will underpin renewed commercial opportunities for drugmakers over a multi-year horizon, with market growth rates expected to return to positive territory in 2017.Headline Expenditure ProjectionsPharmaceuticals: EUR33.46bn (USD37.11bn) in 2015 to EUR33.33bn (USD35.66bn) in 2016; -0.4% in local currency terms and -3.9% in US dollar terms. Forecast revised slightly downwards from last quarter.

Full Report Details at
- http://www.fastmr.com/prod/1172835_france_pharmaceuticals.aspx?afid=301

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q3 2016
- Bahrain Pharmaceuticals & Healthcare Report Q3 2016
- China Pharmaceuticals & Healthcare Report Q3 2016
- Egypt Pharmaceuticals & Healthcare Report Q3 2016